Key takeaways
- A retrospective JAMA Pediatrics study found that GLP-1 use in youth is linked to a 62% higher risk of biliary colic and a 39% higher risk of gallbladder removal.
- The safety signal was especially prominent in adolescents and young adults with class I or class II obesity, showing over a three-fold hazard rate for gallbladder inflammation.
- Researchers attribute the risk to a combination of rapid weight loss and drug-induced gallbladder dysmotility.
- The findings highlight the critical importance of medical screening and symptoms tracking for younger patients utilizing telehealth platforms.
What happened
A new retrospective study published in JAMA Pediatrics has linked the use of GLP-1 receptor agonists in adolescents and young adults to a significantly higher risk of gallbladder and biliary complications. Researchers analyzing real-world health data from more than 37,000 young patients found that those taking these metabolic medications experienced a 62% increased risk of biliary colic and a 39% increased risk of undergoing gallbladder removal surgery compared to matched controls.
Why it matters
As weight-loss drugs like Wegovy and Zepbound surge in popularity, a growing number of adolescents and young adults are turning to these treatments, often seeking access through online telehealth providers. While these medications offer highly effective weight management, this new safety signal underscores the critical need for careful medical screening and ongoing clinical monitoring for younger buyers.
Gallbladder complications can cause severe abdominal pain and may lead to surgical interventions, such as a cholecystectomy (gallbladder removal). For younger individuals purchasing GLP-1 therapies out-of-pocket or through digital platforms, understanding these physical risks is vital before initiating a long-term treatment plan.
What the data says
The retrospective analysis, led by Dr. Josélio Rodrigues de Oliveira Filho of Mass General Brigham and Harvard Medical School, evaluated health records from the TriNetX database spanning January 2022 to May 2026. The researchers focused on youth aged 12 to 21 with a diagnosis of overweight or obesity, establishing propensity-matched cohorts of 18,759 individuals taking GLP-1 medications and an equal number of untreated controls.
Key statistical findings from the study include:
- Biliary Colic: GLP-1 use was associated with a 62% higher relative risk (RR 1.62) of biliary colic (pain caused by gallstones blocking a bile duct).
- Gallbladder Removal: Young users faced a 39% higher relative risk (RR 1.39) of undergoing a cholecystectomy.
- Time-to-Event Analysis: Over time, the hazard ratios (HR) for complications rose even higher for those on GLP-1 therapy, showing a nearly three-fold increase in biliary colic (HR 2.92), more than a two-fold increase in gallbladder inflammation or cholecystitis (HR 2.22), and more than double the hazard for gallbladder surgery (HR 2.39).
- Specific Subgroups: Youths with class I or class II obesity (a BMI between 30 and 39.9) exhibited particularly high hazards over time, including a more than three-fold risk increase for cholecystitis (HR 3.36) and a nearly three-fold hazard for surgical removal (HR 2.93).
The most common GLP-1 prescribed to youths in this cohort was semaglutide (76.7%), followed by liraglutide (14.5%), dulaglutide (8.6%), tirzepatide (3.4%), and exenatide (0.6%). The researchers noted that this elevated risk likely stems from two combined factors: rapid weight loss (which naturally predisposes patients to gallstone formation) and drug-induced gallbladder dysmotility (sluggish emptying of the gallbladder).
How it compares
While adult clinical trials have long documented gallbladder and biliary issues as known GLP-1 side effects, this study confirms a similar safety signal in pediatric populations. The authors pointed out that this risk was first flagged in teens during the STEP TEENS trial, where 4% of adolescent participants on semaglutide (Wegovy) developed acute gallbladder disease, compared to 0% in the placebo group.
In adult populations, the absolute risk remains relatively small. A 2022 meta-analysis of 76 adult clinical trials showed that GLP-1 use added about 27 extra cases of gallbladder disease per 10,000 treated patients per year. However, because younger patients face decades of subsequent metabolic health management, experiencing severe biliary side effects or needing major abdominal surgery early in life presents a distinct clinical burden.
For parents and young buyers comparing brand-name therapies or investigating alternative routes on the cheapest telehealth GLP-1 platforms, these findings emphasize that online weight-loss care cannot simply be a "click-to-prescribe" transaction. It requires robust intake questionnaires and ongoing access to licensed doctors who can evaluate sudden abdominal pain.
How this fits the bigger picture
This pediatric safety data emerges at a time of profound shifts in the metabolic health landscape. Rapid, massive weight loss is historically associated with gallbladder strain, a phenomenon famously documented in bariatric surgery patients. However, as bariatric surgeries plunge as GLP-1 use surges, more patients are experiencing this rapid fat reduction chemically rather than surgically.
Furthermore, as commercial insurance plans tighten their rules and employers cut obesity coverage due to high costs—as detailed in our analysis of the CVS Health employer benefits survey—more young adults are forced to pay cash. To save money, some consumers look into low-cost alternatives or attempt unauthorized GLP-1 microdosing to stretch their prescriptions. However, bypassing standard medical supervision and structured titration schedules could make it harder to spot emerging symptoms of biliary colic or gallbladder inflammation before they escalate into surgical emergencies.
What happens next
The study's authors emphasized that because this was a retrospective trial using diagnostic codes, further prospective research is required to establish direct causality. Future trials will need to evaluate whether preventative strategies used in bariatric surgery patients—such as prescribing gallbladder-protective medications during active weight loss—could benefit younger GLP-1 users.
In the meantime, researchers recommend that physicians and telehealth clinicians remain highly vigilant. Younger patients taking these medications, along with their guardians, should be closely educated on the signs of biliary disease, including sharp upper-abdominal pain, nausea, and vomiting, to ensure rapid medical evaluation if symptoms arise.
Disclaimer: CompareRx does not provide medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication regimen.